Pfizer Inc. says it has agreed to buy King Pharmaceuticals Inc. for $3.6 billion in cash.
The price for the Tennessee drugmaker represents a hefty 40 percent premium over King's closing price on Monday. It would broaden Pfizer's array of painkillers and drug delivery devices.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.